Traductor

Showing posts with label marihuana. Show all posts
Showing posts with label marihuana. Show all posts

19 April 2012

Marijuana Use Higher in Young Adult Smokers Than Previously Reported



Other recent studies have shown that approximately 35 percent of young adult tobacco smokers used marijuana within the last month.

“We were curious whether rates would be different in our study where we reached out through social media and the Web,” said lead author Danielle Ramo, PhD, a post-doctoral scholar in the UCSF Department of Psychiatry. “And rates were much higher, which shows the problem might be larger than we realize.”

Survey participants were recruited solely online, a departure from traditional surveys that rely on face to-face interviews, phone interviews or completing questionnaires. The UCSF researchers primarily used Facebook through a series of paid advertisements, in addition to Craigslist and a survey sampling company to reach out to young adults. The results, the researchers said, indicate young adults might be more inclined to answer honestly via anonymous online sampling.

The research will be published in Addiction Science and Clinical Practice on April 18.

The first phase of the survey was used to identify tobacco smoking patterns only. A second stage asked participants to answer the tobacco and marijuana use survey, which employed data encryption to ensure anonymity and prevent multiple entries. Of the 3,500 individuals who completed the marijuana and tobacco co-use survey, usage was highest amongst Caucasians, people from the Northeast, people in rural areas and among the non-student population. Of the 68 percent who were daily smokers, 53 percent had used marijuana in the last month.

“Residence in a medical marijuana state was unrelated to the prevalence of marijuana use as well as the co-use of marijuana and tobacco in this young adult sample,” reported Judith Prochaska, PhD, MPH, associate professor of psychiatry at UCSF and the study’s senior author. “The prevalence of marijuana use also did not differ by respondents’ age, income or gender.”

The research shows that smoking cessation programs aimed at this age group should take into account the effect of marijuana use in their programs, according to Ramo. The next phase of the research is to adapt behavioral and cognitive principles for smoking cessation, like counseling, to Facebook.

“Adapting the social media aspect into intervention and incorporating the social environment are new ways to approach finding the most effective means for treatment,” she said.

Ramo and Prochaska plan to use social media such as Facebook, in which participants will be able to contact not only the clinicians for support, but also other smokers within the online community. Motivational Facebook messages and formal moderated groups online also will be integrated into treatment.

“This format allows them to remain anonymous as much as they want, but have ease to access interventions when they are at the age when they are less likely to enter a treatment center, research lab or clinic,” Ramo said.

The study was supported by an institutional training grant, a center grant from the National Institute on Drug Abuse and an individual Postdoctoral Fellowship Award from the California Tobacco-Related Diseases Research Program. The authors have no competing interests related to this research.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

**Published in "SCIENCE DAILY!"

22 March 2012

Marijuana-like chemicals inhibit human immunodeficiency virus in late-stage AIDS


Mount Sinai School of Medicine researchers have discovered that marijuana-like chemicals trigger receptors on human immune cells that can directly inhibit a type of human immunodeficiency virus (HIV) found in late-stage AIDS, according to new findings published online in the journal PLoS ONE. Medical marijuana is prescribed to treat pain, debilitating weight loss and appetite suppression, side effects that are common in advanced AIDS. This is the first study to reveal how the marijuana receptors found on immune cells -- called cannabinoid receptors CB1 and CB2 -- can influence the spread of the virus. Understanding the effect of these receptors on the virus could help scientists develop new drugs to slow the progression of AIDS.
"We knew that cannabinoid drugs like marijuana can have a therapeutic effect in AIDS patients, but did not understand how they influence the spread of the virus itself," said study author Cristina Costantino, PhD, Postdoctoral Fellow in the Department of Pharmacology and Systems Therapeutics at Mount Sinai School of Medicine. "We wanted to explore cannabinoid receptors as a target for pharmaceutical interventions that treat the symptoms of late-stage AIDS and prevent further progression of the disease without the undesirable side effects of medical marijuana."
HIV infects active immune cells that carry the viral receptor CD4, which makes these cells unable to fight off the infection. In order to spread, the virus requires that "resting" immune cells be activated. In advanced AIDS, HIV mutates so it can infect these resting cells, gaining entry into the cell by using a signaling receptor called CXCR4. By treating the cells with a cannabinoid agonist that triggers CB2, Dr. Costantino and the Mount Sinai team found that CB2 blocked the signaling process, and suppressed infection in resting immune cells.
Triggering CB1 causes the drug high associated with marijuana, making it undesirable for physicians to prescribe. The researchers wanted to explore therapies that would target CB2 only. The Mount Sinai team infected healthy immune cells with HIV, then treated them with a chemical that triggers CB2 called an agonist. They found that the drug reduced the infection of the remaining cells.
"Developing a drug that triggers only CB2 as an adjunctive treatment to standard antiviral medication may help alleviate the symptoms of late-stage AIDS and prevent the virus from spreading," said Dr. Costantino. Because HIV does not use CXCR4 to enhance immune cell infection in the early stages of infection, CB2 agonists appear to be an effective antiviral drug only in late-stage disease.

**Source: Mount Sinai Medical Center

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud